– 2016 Aegis Growth Conference Presentation with Live Webcast on Wednesday, September 21 at 10:30 a.m. PT –
– OktoberINVESTfest Presented by Joseph Gunnar 5th Annual Investors Conference Presentation with Live Webcast on Wednesday, September 28 at 5:20 p.m. ET –
TORONTO and BOSTON, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Bionik Laboratories Corp. (OTCQX:BNKL) (“Bionik” or the "Company"), a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders announced today that Peter Bloch, Chief Executive Officer and Chairman of the Board will present at two upcoming investor conferences in September.
During his presentations, Mr. Bloch will provide a corporate update and discuss Bionik's product portfolio focused on upper and lower extremity rehabilitation for stroke and paraplegic patients, including the Company’s three commercial products on the market and three products in development.
Event: 2016 Aegis Growth Conference
Date: Wednesday, September 21, 2016
Time: 10:30 a.m. Pacific Time
Location: The Encore at Wynn Las Vegas, Las Vegas, NV
Event: OktoberINVESTfest presented by Joseph Gunnar 5th Annual Investors Conference
Date: Wednesday, September 28, 2016
Time: 5:20 p.m. Eastern Time
Location: The New York Academy of Sciences, New York, NY
Live webcasts of both presentations will be available on Bionik's IR Calendar in the Investor Relations section of the Company's website (www.bioniklabs.com). The webcast replays will be available for approximately two hours after the presentations end and will be archived for 30 days.
About Bionik Laboratories
Bionik Laboratories (OTCQX:BNKL), is a global, pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and paraplegic patients, including three products on the market and three products in varying stages of development. The InMotion Systems - the InMotion ARM™, InMotionWrist™, InMotion Hand™ and InMotion Ankle™, are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™, designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. ARKE is expected to be designed to continually adapt to a patient’s ability and provide real time feedback to the physiotherapist through the use of Bionik’s proprietary data collection and analytics cloud network through its partnership with IBM.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the successful integration of IMT with Bionik and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Last updated on: 15/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.